Rapha Capital Management Launches First Fund Focused on Early-Stage Biotech Startups

Rapha Capital Management

Rapha Capital Management, a Miami, FL-based investment management firm focused on life sciences, launched its first managed venture capital fund, with a target raise of $100M. 

Rapha Capital BioVentures Fund I, LP, is solely focused on investment in early-stage life science companies. The fund will focus on securing the investment lead, typically at Series A or just before, in target companies.

Kevin Slawin, MD, the Founder and Managing Partner of Rapha Capital Management, LLC is an oncologic and robotic surgeon, biotech consultant, investor, and founder focusing on disruptive technologies in oncology, T cells and immunotherapy, as well as other breakthrough healthcare technologies. He is the founder of Bellicum Pharmaceuticals, Inc., a company listed on the NASDAQ, and led Bellicum to a successful $161 million IPO in December, 2014. He also serves as a board member at 3DBio Therapeutics, FIZE Medical, and Demeetra AgBio. He served as a board member and interim CEO of portfolio company AsclepiX Therapeutics, in 2020, engineering their $35m Series A financing led by Perceptive Xontogeny Venture Fund in mid 2020.